2020
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.
Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, Parker T, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder J, Faber E, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar S. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. Journal Of Clinical Oncology 2020, 38: lba3-lba3. DOI: 10.1200/jco.2020.38.18_suppl.lba3.Peer-Reviewed Original ResearchProgression-free survivalPhase III trialsInitial therapyIII trialsHazard ratioMedian progression-free survivalRandomized phase 3 trialRandomized phase III trialNext-generation proteasome inhibitorsDexamethasone Versus BortezomibStandard initial therapyPhase 3 trialPhase II trialPlasma cell leukemiaISS stageLen-DexLens maintenanceNeuropathy ratesInduction regimenFree survivalII trialPFS eventsMedian ageMultiple myelomaRenal toxicity
2019
Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.Peer-Reviewed Original ResearchOverall survivalMultiple myelomaPerformance statusMultivariable Cox survival analysisMedian overall survivalPoor performance statusLines of therapyKaplan-Meier methodCox regression analysisDays of diagnosisWorse overall survivalCox survival analysisLog-rank testReal-world treatmentCommon genetic mutationsHigh-risk mutationsSitu hybridization testingElectronic health recordsISS stageReal-world practiceMedian ageMeier methodOS independentPrimary outcomeSpecific regimens
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply